GlassScriptPhysician profile
Gathline Etienne
NPI 1366602005
$128,186.74
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,536 · 2020: $42K · 2021: $36K · 2022: $29K · 2023: $12K · 2024: $62.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,520 · Consulting Fee: $1,188 · Food and Beverage: $898 · Travel and Lodging: $29.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,520.00 |
| Consulting Fee | $1,188.00 |
| Food and Beverage | $898.25 |
| Travel and Lodging | $29.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $37,691.09 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $29,572.96 | 2019-2023 | Ultomiris, Soliris |
| Allergan, INC. | $29,307.80 | 2019-2022 | |
| Biogen, INC. | $26,398.06 | 2019-2022 | |
| Argenx US, INC. | $1,206.47 | 2023 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $456.64 | 2019-2023 | |
| Ucb, INC. | $416.67 | 2019-2024 | Briviact |
| Sk Life Science, INC. | $226.30 | 2021-2022 | |
| Amgen INC. | $178.83 | 2019-2022 | |
| Genzyme Corporation | $169.56 | 2019-2022 | |
| Greenwich Biosciences, INC. | $160.34 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $148.82 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $145.31 | 2019-2023 | Austedo Xr, Austedo |
| Lilly USA, LLC | $134.18 | 2019-2023 | Amyvid |
| Lundbeck LLC | $124.31 | 2019-2023 | Vyepti |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gathline Etienne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.